AdAlta (ASX:1AD) has announced the continuation of its collaboration with The Alfred hospital in Melbourne and the clinical research team led by Dr Glen Westall.
Dr Westall is an expert in lung fibrosis and Idiopathic Pulmonary Fibrosis (IPF).
Fibrosis accounts for 45 per cent of all diseases globally in the developed world and represents a large unmet medical need.
The expanded collaboration, designed to further validate AD-114’s role in the treatment of IPF, will run for an additional six months and be funded by the company and an Innovation Connection grant from the Australian government.
According to AdAlta CEO, Sam Cobb, “Our multiple collaborations and strategic alliances across commercial, clinical and manufacturing areas with world-leading partners, such as the team at The Alfred, further enhance the potential for the success of our new treatments for fibrosis.”
Dr Westall and his team are international leaders in the field of lung fibrosis with access to human IPF patient tissue for evaluation with AdAlta’s lead candidate AD-114.
“We are excited to continue working with AdAlta to further understand this complex fibrotic disease and how the Company’s novel i-body may play a role in the treatment of IPF, for which there is currently no cure,” said Dr Westall.